Isoniazid probably leads to lower tuberculosis compared with no treatment (moderate certainty).
Isoniazid probably leads to higher INH hepatotoxicity Jaundice, elevated bilirubin, elevated liver… compared with no treatment (moderate certainty).
Isoniazid showed no clear difference in all‐cause mortality compared with no treatment (low certainty).
Angiotensin receptor blockers (ARBs) showed no clear difference in adverse events (episodes of peritonitis) compared with conventional therapy (low certainty).
Angiotensin‐converting enzyme inhibitors (ACEi) probably leads to lower anuria compared with conventional therapy (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in mortality compared with conventional therapy (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in cardiac events compared with conventional therapy (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in cardiac events (fatal) compared with conventional therapy (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in cardiac events (non fatal) compared with conventional therapy (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in adverse events (episodes of peritonitis) compared with conventional therapy (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in adverse events (episodes of peritonitis) ‐ treated with an… compared with conventional therapy (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in adverse events (episodes of peritonitis) ‐ not treated with an… compared with conventional therapy (moderate certainty).
Angiotensin receptor blockers (ARBs) showed no clear difference in anuria compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).
Angiotensin receptor blockers (ARBs) showed no clear difference in cardiovascular events (non‐fatal) compared with angiotensin‐converting enzyme inhibitors (ACEis) (moderate certainty).